Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461

  • Authors:
    • Sherif S. Farag
    • Kellie J. Archer
    • Krzysztof Mrozek
    • James W. Vardiman
    • Andrew J. Carroll
    • Mark J. Pettenati
    • Joseph O. Moore
    • Jonathan E. Kolitz
    • Robert J. Mayer
    • Richard M. Stone
    • Richard A. Larson
    • Clara D. Bloomfield
  • View Affiliations

  • Published online on: November 1, 2002     https://doi.org/10.3892/ijo.21.5.1041
  • Pages: 1041-1051
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Isolated trisomy is a relatively common cytogenetic abnormality in acute myeloid leukemia (AML), but with uncertain prognostic significance. We studied a large cohort of newly diagnosed de novo AML patients karyotyped on CALGB 8461 from 1984-1999, where trisomy was the sole abnormality. The common isolated trisomies (ITC), +8, +11, +13 and +21, comprised 90% of all sole trisomies. The outcome of 101 ITC patients was compared to that of 976 with normal and cytogenetics. The overall survival (OS) for ITC patients was unsatisfactory with 10% [95% confidence interval (CI), 3-17%] alive at 5 years. Repeated cycles of I/HDAC intensification did not improve outcome. However, SCT significantly improved relapse-free survival (RFS). Among ITC patients <60 years in first remission, only 1 of 7 receiving SCT relapsed, compared to 16 of 19 patients treated with chemotherapy only. The prognosis of ITC was dependent on SCT. For non-transplanted patients, the 5-year OS for ITC was 5% (95% CI, 0-11%), compared to 20% (95% CI, 16-23%) for 640 normal cytogenetics patients. ITC was an independent adverse prognostic factor for OS in non-transplanted patients. In those receiving SCT, however, the 5-year OS for ITC patients (69%, 95% CI, 32-100%) was not different to that of transplanted normal cytogenetics patients (60%, 95% CI, 38-81%). We conclude that in de novo adult AML patients not receiving SCT, ITC appears to independently predict a poor outcome that may be improved with SCT in first remission. Prospective studies are required to confirm this hypothesis.

Related Articles

Journal Cover

November 2002
Volume 21 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Farag SS, Archer KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, Moore JO, Kolitz JE, Mayer RJ, Stone RM, Stone RM, et al: Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Int J Oncol 21: 1041-1051, 2002
APA
Farag, S.S., Archer, K.J., Mrozek, K., Vardiman, J.W., Carroll, A.J., Pettenati, M.J. ... Bloomfield, C.D. (2002). Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. International Journal of Oncology, 21, 1041-1051. https://doi.org/10.3892/ijo.21.5.1041
MLA
Farag, S. S., Archer, K. J., Mrozek, K., Vardiman, J. W., Carroll, A. J., Pettenati, M. J., Moore, J. O., Kolitz, J. E., Mayer, R. J., Stone, R. M., Larson, R. A., Bloomfield, C. D."Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461". International Journal of Oncology 21.5 (2002): 1041-1051.
Chicago
Farag, S. S., Archer, K. J., Mrozek, K., Vardiman, J. W., Carroll, A. J., Pettenati, M. J., Moore, J. O., Kolitz, J. E., Mayer, R. J., Stone, R. M., Larson, R. A., Bloomfield, C. D."Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461". International Journal of Oncology 21, no. 5 (2002): 1041-1051. https://doi.org/10.3892/ijo.21.5.1041